Document is current

Article History

Received: 3 May 2024

Accepted: 20 July 2024

First Online: 29 July 2024

Declarations

:

: The study obtained approval from the Advarra Institutional Review Board and all participants gave written informed consent prior to study participation.

: Not applicable.

: JER, GC, PNW, TLB and DRB are employees of Rose Research Center (RRC). RRC is an independent contract research organization that performs studies pertaining to smoking cessation and tobacco harm reduction. Other research support: National Institute on Drug Abuse; Foundation for a Smoke-Free World, Inc. (“FSFW”), a US nonprofit 501(c)(3) private foundation; Nicotine BRST LLC; JUUL Labs; Altria; Embera Neurotherapeutics, Inc.; Otsuka Pharmaceutical; Swedish Match, Philip Morris International. JER, FMB, TLB, DRB: Patent applications filed for bupropion/zonisamide and related drug combinations. JER, FMB: Patent purchase agreement with Philip Morris International for nicotine inhalation system patents, final payment 2014. JER, FMB: Patent payments from Novartis through University of California patent license for nicotine skin patch, final payment 2008. RRC is the developer of the eResearch integrated digital platform for decentralized clinical trials of stop smoking products. JER Consulting: Philip Morris International, JT International, SA. GC was previously a Principal Scientist at JUUL Labs, a developer of non-combusted tobacco products, and was previously employed by its predecessor companies. He also was employed at Nektar Therapeutics, whose pipeline included an inhaled NRT. Stock holdings in Qnovia, a developer of an inhaled NRT, and JUUL Labs.